BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...after another sGC stimulator failed in a different population of HF patients. On Oct. 30, Cyclerion Therapeutics Inc....
BioCentury | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

...Ironwood. Despite the miss for praliciguat, the company sees signs of optimism for the platform. Cyclerion Therapeutics Inc....
...this tells us that we’re hitting the right range,” Currie told BioCentury. Erin McCallister, Senior Editor Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Soluble...
BioCentury | May 20, 2019
Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

...model, praliciguat decreased steatosis and levels of a marker of liver fibrosis. Next steps by Cyclerion Therapeutics Inc....
...doi:10.1073/pnas.1821045116 CONTACT: Katherine C. Hall, Ironwood Pharmaceuticals Inc. and Cyclerion Therapeutics Inc., Cambridge, Mass. e-mail: khall@cyclerion.com Sandi Wong Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Soluble...
BioCentury | May 14, 2019
Preclinical News

Cyclerion's sGC activation could work for NASH

...Ironwood-spinout Cyclerion is making the case for extending its lead sGC stimulator praliciguat into NASH. Cyclerion Therapeutics Inc....
...optimize pharmacology but has not chosen a specific liver indication, Wright added. Sandi Wong, Staff Writer Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Ironwood...
BioCentury | Apr 12, 2019
Financial News

Cyclerion launches, raises $175M private placement

...pipeline for at least two years (see "Ironwood Spinout Cyclerion Planning $175M Private Placement" ). Cyclerion Therapeutics Inc....
...Pharmaceuticals Inc. (NASDAQ:IRWD) retains its gastrointestinal business (see "Splitting Ironwood" ). Mary Romeo, Staff Writer IW-6463 olinciguat (IW-1701) Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Ironwood...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

...Peter Hecht and President and CSO Mark Currie. In conjunction with its April 2 launch, Cyclerion Therapeutics Inc....
...as CEO. He was an independent non-executive member of the board. BioCentury Staff Alder BioPharmaceuticals Inc. Alkermes plc Chimerix Inc. Cyclerion Therapeutics Inc. Polyphor...
BioCentury | Feb 28, 2019
Financial News

Ironwood spinout Cyclerion planning $175M private placement

...Ironwood was off $0.43 to $14.08 on Feb. 26. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Cyclerion Therapeutics Inc....
BioCentury | Feb 26, 2019
Financial News

Ironwood spinout Cyclerion planning $175M private placement

...Ironwood was off $0.43 to $14.08 on Tuesday. Hongjiang Li IW-1701 IW-6463 Praliciguat, IW-1973 Ironwood Pharmaceuticals Inc. Soluble guanylate cyclase (sGC) Cyclerion Therapeutics Inc....
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will...
BioCentury | Jan 4, 2019
Company News

AZ’s Mallon to lead Ironwood; Hecht to helm spinout

...GI company said co-founder and CEO Peter Hecht will become CEO of the company's spinout Cyclerion Therapeutics Inc....
Items per page:
1 - 10 of 10
BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...after another sGC stimulator failed in a different population of HF patients. On Oct. 30, Cyclerion Therapeutics Inc....
BioCentury | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

...Ironwood. Despite the miss for praliciguat, the company sees signs of optimism for the platform. Cyclerion Therapeutics Inc....
...this tells us that we’re hitting the right range,” Currie told BioCentury. Erin McCallister, Senior Editor Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Soluble...
BioCentury | May 20, 2019
Distillery Therapeutics

Cyclerion's sGC stimulator praliciguat ameliorates NASH in rodents

...model, praliciguat decreased steatosis and levels of a marker of liver fibrosis. Next steps by Cyclerion Therapeutics Inc....
...doi:10.1073/pnas.1821045116 CONTACT: Katherine C. Hall, Ironwood Pharmaceuticals Inc. and Cyclerion Therapeutics Inc., Cambridge, Mass. e-mail: khall@cyclerion.com Sandi Wong Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Soluble...
BioCentury | May 14, 2019
Preclinical News

Cyclerion's sGC activation could work for NASH

...Ironwood-spinout Cyclerion is making the case for extending its lead sGC stimulator praliciguat into NASH. Cyclerion Therapeutics Inc....
...optimize pharmacology but has not chosen a specific liver indication, Wright added. Sandi Wong, Staff Writer Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Ironwood...
BioCentury | Apr 12, 2019
Financial News

Cyclerion launches, raises $175M private placement

...pipeline for at least two years (see "Ironwood Spinout Cyclerion Planning $175M Private Placement" ). Cyclerion Therapeutics Inc....
...Pharmaceuticals Inc. (NASDAQ:IRWD) retains its gastrointestinal business (see "Splitting Ironwood" ). Mary Romeo, Staff Writer IW-6463 olinciguat (IW-1701) Praliciguat, IW-1973 Cyclerion Therapeutics Inc. Ironwood...
BioCentury | Apr 9, 2019
Company News

Management tracks: Cyclerion, Alkermes, Alder

...Peter Hecht and President and CSO Mark Currie. In conjunction with its April 2 launch, Cyclerion Therapeutics Inc....
...as CEO. He was an independent non-executive member of the board. BioCentury Staff Alder BioPharmaceuticals Inc. Alkermes plc Chimerix Inc. Cyclerion Therapeutics Inc. Polyphor...
BioCentury | Feb 28, 2019
Financial News

Ironwood spinout Cyclerion planning $175M private placement

...Ironwood was off $0.43 to $14.08 on Feb. 26. Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Cyclerion Therapeutics Inc....
BioCentury | Feb 26, 2019
Financial News

Ironwood spinout Cyclerion planning $175M private placement

...Ironwood was off $0.43 to $14.08 on Tuesday. Hongjiang Li IW-1701 IW-6463 Praliciguat, IW-1973 Ironwood Pharmaceuticals Inc. Soluble guanylate cyclase (sGC) Cyclerion Therapeutics Inc....
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) named Mark Currie as incoming president of its spinout Cyclerion Therapeutics Inc. Currie will...
BioCentury | Jan 4, 2019
Company News

AZ’s Mallon to lead Ironwood; Hecht to helm spinout

...GI company said co-founder and CEO Peter Hecht will become CEO of the company's spinout Cyclerion Therapeutics Inc....
Items per page:
1 - 10 of 10